Twelve active RA patients were available for examination of their expression levels of MDL-1 and DAP12 in the active phase (baseline time-point) and after 9–12 months of therapy with triple DMARDs, including methotrexate, hydroxychloroquine, and sulfasalazine. This evidence concerns the gene CLEC5A and rheumatoid arthritis.